Osteoarthritis in Dogs
Lifetime Risk
● Osteoarthritis (OA) and related pain affect 15-25% of dogs
● OA affects 80% of dogs aged 8 years and older
Current Therapies
● Current therapies generally are focused on treating the pain associated
with OA and not repairing damage to cartilage, bone or the synovial lining of the joint
● These therapies include nonsteroidal anti-inflammatory drugs (NSAIDs) and even the recently approved monoclonal antibody therapies targeting nerve growth factor (NGF)
● Regenerative therapies based on stem cells, platelet rich plasma, and other approaches hold promise, but frequently have not been tested to establish substantial evidence for regulatory approval
Biologic Approaches for Disease Modification
● Disease modifying osteoarthritis drugs (DMOADs) are the next generation of therapeutic options
● These may include targeted monoclonal antibodies, peptides, proteins or gene therapy that, depending on the target, add or block growth factors and cytokines involved in joint health
● The goal of biologic approaches is to shift from a state of joint destruction to one that is regenerative and repairs cartilage, bone and the synovial lining